close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Skye Bioscience, Inc. - Common Stock (OP:SKYE)

N/A UNCHANGED
Last Price Updated: 3:57 PM EDT, Apr 10, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Skye Bioscience, Inc. - Common Stock

< Previous 1 2 3 Next >
News headline image
Skye Bioscience Announces $40 Million Private Placement Equity Financing
San Diego, California--(Newsfile Corp. - March 11, 2024) - Skye Bioscience, Inc. (OTCQB: SKYE) (the Company), a clinical stage biotechnology... 
Via Newsfile
News headline image
Skye Bioscience to Present at Oppenheimer Investor Conference
San Diego, California--(Newsfile Corp. - February 7, 2024) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye"), a clinical-stage biotechnology company focused... 
Via Newsfile
News headline image
Skye Bioscience And 2 Other Penny Stocks Insiders Are Buying ↗
The Dow Jones index closed higher by more than 100 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and... 
Via Benzinga
Topics Stocks
News headline image
Skye Bioscience Announces $50.25 Million Private Placement Equity Financing
San Diego, California--(Newsfile Corp. - January 29, 2024) - Skye Bioscience, Inc. (OTCQB: SKYE) ("the Company"), a clinical stage biotechnology... 
Via Newsfile
News headline image
Skye Bioscience Receives IND Clearance for Phase 2 Clinical Trial of Nimacimab in Obesity and Chronic Kidney Disease
San Francisco, California--(Newsfile Corp. - January 9, 2024) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical... 
Via Newsfile
News headline image
Skye Bioscience and Tautomer Bioscience Enter Exclusive License for SBI-100 for Development and Sale of Products for Chronic Pain and Other Indications in South Africa and Rest of Africa
San Diego, California and Johannesburg, South Africa--(Newsfile Corp. - December 5, 2023) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye"), a... 
Via Newsfile
Topics Cannabis Intellectual Property
News headline image
Skye Bioscience to Present at BTIG Ophthalmology Day and OIS XIII Ophthalmology Innovation Summit
San Diego, California--(Newsfile Corp. - November 21, 2023) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye"), a pharmaceutical company developing drugs... 
Via Newsfile
News headline image
Skye Bioscience Announces Positive Phase 1 Trial Results for SBI-100 Ophthalmic Emulsion, Its First-in-Class CB1 Agonist Being Developed for the Treatment of Glaucoma
• SBI-100 OE is well tolerated, with low rate of hyperaemia... 
Via Newsfile
News headline image
CORRECTION: Skye Bioscience to Host Virtual Investor Day on October 25, 2023: "CB1 Axis: Unlocking the Pharmaceutical Potential of the Endocannabinoid System"
This document replaces and updates the previous version with the current OTCQB ticker for Skye Bioscience, Inc.San Diego, California--(Newsfile Corp.... 
Via Newsfile
News headline image
Skye Bioscience to Present at H.C. Wainwright 25th Annual Global Investment Conference
San Diego, California--(Newsfile Corp. - September 5, 2023) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye"), a pharmaceutical company developing proprietary... 
Via Newsfile
News headline image
Marijuana Stock Movers For August 23, 2023 ↗
 
Via Benzinga
Topics Cannabis
News headline image
Cannabis Stock Gainers And Losers From August 25, 2023 ↗
 
Via Benzinga
Topics Cannabis
News headline image
Skye Secures $17M And Acquires Novel Phase 2-Ready Cannabinoid 1 Receptor Inhibitor ↗
Skye Bioscience, Inc. (OTCQB: SKYE) has undertaken a strategic initiative that expands the company's resources and technologies focused on developing therapeutic products focused on the endocannabinoid... 
Via Benzinga
News headline image
Skye Completes $17M Financing and Acquires Novel Phase 2-Ready CB1-Inhibiting Monoclonal Antibody
New capital funds anticipated Phase 2a glaucoma clinical trial Nimacimab is a first-in-class peripherally-restricted negative allosteric modulator antibody inhibitor of... 
Via Newsfile
News headline image
Cannabis Stock Gainers And Losers From August 24, 2023 ↗
 
Via Benzinga
Topics Cannabis
News headline image
Cannabis Stock Movers For August 18, 2023 ↗
 
Via Benzinga
Topics Cannabis
News headline image
Marijuana Stock Movers For August 22, 2023 ↗
 
Via Benzinga
Topics Cannabis
News headline image
Skye Bioscience to Present at H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference
San Diego, California--(Newsfile Corp. - August 14, 2023) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye"), a pharmaceutical company developing a... 
Via Newsfile
News headline image
Bearish Monday For Marijuana Stocks - EVIO, Item 9 Labs Among Top Gainers ↗
 
Via Benzinga
News headline image
Bearish Sentiment Across The Cannabis Space - Check Full Movers For August 21, 2023 ↗
 
Via Benzinga
Topics Cannabis
News headline image
Bullish Thursday For Marijuana Stocks - EVIO, Tetra Bio Pharma Among Top Gainers ↗
 
Via Benzinga
Topics Cannabis
News headline image
Cannabis Stock Gainers And Losers From August 16, 2023 ↗
 
Via Benzinga
Topics Cannabis
News headline image
Cannabis Stock Gainers And Losers From August 14, 2023 ↗
 
Via Benzinga
Topics Cannabis
News headline image
Cannabis Stock Gainers And Losers From August 11, 2023 ↗
 
Via Benzinga
Topics Cannabis
News headline image
Marijuana Stock Movers For August 8, 2023 ↗
 
Via Benzinga
News headline image
Marijuana Stock Movers For August 2, 2023 ↗
 
Via Benzinga
News headline image
Marijuana Stock Movers For August 1, 2023 ↗
 
Via Benzinga
News headline image
Marijuana Stock Movers For July 31, 2023 ↗
 
Via Benzinga
News headline image
Cannabis Stock Gainers And Losers From July 28, 2023 ↗
 
Via Benzinga
News headline image
Cannabis Stock Gainers And Losers From July 26, 2023 ↗
 
Via Benzinga
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today